Mark Harries

7.1k total citations
62 papers, 1.9k citations indexed

About

Mark Harries is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Mark Harries has authored 62 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Oncology, 17 papers in Cancer Research and 15 papers in Molecular Biology. Recurrent topics in Mark Harries's work include Cutaneous Melanoma Detection and Management (19 papers), CAR-T cell therapy research (12 papers) and Melanoma and MAPK Pathways (11 papers). Mark Harries is often cited by papers focused on Cutaneous Melanoma Detection and Management (19 papers), CAR-T cell therapy research (12 papers) and Melanoma and MAPK Pathways (11 papers). Mark Harries collaborates with scholars based in United Kingdom, United States and Germany. Mark Harries's co-authors include Martin Gore, Ian Smith, Mary Collins, Arnie Purushotham, Stanley B. Kaye, James Spicer, K. Acland, Andrew O. Agbaje, Lars Holmberg and Hans Garmo and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Journal of Virology.

In The Last Decade

Mark Harries

60 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Harries United Kingdom 25 1.1k 579 354 337 317 62 1.9k
Marta Gil-Martín Spain 20 1.2k 1.1× 629 1.1× 228 0.6× 324 1.0× 322 1.0× 108 2.0k
Paula R. Pohlmann United States 22 1.3k 1.2× 655 1.1× 335 0.9× 321 1.0× 489 1.5× 100 2.3k
Franco Di Filippo Italy 25 847 0.8× 477 0.8× 254 0.7× 178 0.5× 266 0.8× 80 1.9k
Thierry Petit France 24 1.3k 1.3× 542 0.9× 143 0.4× 270 0.8× 718 2.3× 133 2.2k
Alberto Gallardo Spain 28 822 0.8× 1.1k 1.9× 394 1.1× 225 0.7× 440 1.4× 70 2.4k
Juan J. Roman United States 23 728 0.7× 568 1.0× 599 1.7× 208 0.6× 191 0.6× 27 1.8k
Natália Buza United States 33 1.2k 1.1× 673 1.2× 258 0.7× 350 1.0× 325 1.0× 134 2.9k
Richard Lubin France 18 1.1k 1.1× 615 1.1× 383 1.1× 327 1.0× 321 1.0× 24 1.8k
Jean‐Pascal Machiels Belgium 23 808 0.8× 461 0.8× 170 0.5× 178 0.5× 256 0.8× 58 1.6k
Christian Rudlowski Germany 23 478 0.5× 527 0.9× 267 0.8× 115 0.3× 422 1.3× 61 1.6k

Countries citing papers authored by Mark Harries

Since Specialization
Citations

This map shows the geographic impact of Mark Harries's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Harries with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Harries more than expected).

Fields of papers citing papers by Mark Harries

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Harries. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Harries. The network helps show where Mark Harries may publish in the future.

Co-authorship network of co-authors of Mark Harries

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Harries. A scholar is included among the top collaborators of Mark Harries based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Harries. Mark Harries is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bolte, Laura A., Karla A. Lee, Johannes R. Björk, et al.. (2023). Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma. JAMA Oncology. 9(5). 705–705. 51 indexed citations
2.
Fitzpatrick, Amanda, Marjan Iravani, Lucy Childs, et al.. (2021). Assessing CSF ctDNA to Improve Diagnostic Accuracy and Therapeutic Monitoring in Breast Cancer Leptomeningeal Metastasis. Clinical Cancer Research. 28(6). 1180–1191. 44 indexed citations
3.
4.
Garmo, Hans, Matthew R. Young, Massimiliano Cariati, et al.. (2020). Invasive breast cancer over four decades reveals persisting poor metastatic outcomes in treatment resistant subgroup – the “ATRESS” phenomenon. The Breast. 50. 39–48. 9 indexed citations
5.
Markopoulos, Christos, David M. Hyams, Henry Gómez, et al.. (2019). Multigene assays in early breast cancer: Insights from recent phase 3 studies. European Journal of Surgical Oncology. 46(4). 656–666. 20 indexed citations
6.
Winter, Helen, Sharmin Rahman, John Conibear, et al.. (2018). Virtual metastatic breast multidisciplinary meeting: The next step in personalised medicine.. Journal of Clinical Oncology. 36(15_suppl). e18794–e18794. 1 indexed citations
7.
Harries, Mark, Josep Malvehy, Célèste Lebbé, et al.. (2016). Treatment patterns of advanced malignant melanoma (stage III–IV) – A review of current standards in Europe. European Journal of Cancer. 60. 179–189. 40 indexed citations
8.
Fink, Leah, Justyna Amelio, Mark Harries, et al.. (2016). Making decisions on resectability and injectability status of lesions in the management of advanced melanoma in Germany, France and the UK. European Journal of Dermatology. 26(5). 477–486. 1 indexed citations
9.
Cariati, Massimiliano, Maarten Grootendorst, A. Michael Peters, et al.. (2015). Adjuvant taxanes and the development of breast cancer-related arm lymphoedema. British journal of surgery. 102(9). 1071–1078. 49 indexed citations
10.
Harries, Mark, Peter Mohr, Florent Grange, et al.. (2014). Economic Burden of Melanoma in Three European Countries: A Retrospective Observational Study. Value in Health. 17(7). A626–A626. 1 indexed citations
11.
Harries, Mark, Aliki Taylor, Lars Holmberg, et al.. (2014). Incidence of bone metastases and survival after a diagnosis of bone metastases in breast cancer patients. Cancer Epidemiology. 38(4). 427–434. 62 indexed citations
12.
Purushotham, Arnie, Eamon Shamil, Massimiliano Cariati, et al.. (2014). Age at diagnosis and distant metastasis in breast cancer – A surprising inverse relationship. European Journal of Cancer. 50(10). 1697–1705. 70 indexed citations
13.
Purushotham, Arnie, et al.. (2010). Neoadjuvant Chemotherapy: Not the Best Option in Estrogen Receptor–Positive, HER2-Negative, Invasive Classical Lobular Carcinoma of the Breast?. Journal of Clinical Oncology. 28(22). 3552–3554. 36 indexed citations
14.
Sarker, Shah‐Jalal, et al.. (2009). Predictors of patient satisfaction with initial diagnosis and management of malignant melanoma. Clinical and Experimental Dermatology. 35(6). 599–602. 6 indexed citations
15.
Laggner, Ute, Juanita Lopez, G. Perera, et al.. (2009). Regression of melanoma metastases following treatment with the n-bisphosphonate zoledronate and localised radiotherapy. Clinical Immunology. 131(3). 367–373. 23 indexed citations
16.
Constantinidou, Anastasia, Michael S. Hofman, Michael O’Doherty, et al.. (2008). Routine positron emission tomography and positron emission tomography/computed tomography in melanoma staging with positive sentinel node biopsy is of limited benefit. Melanoma Research. 18(1). 56–60. 26 indexed citations
17.
18.
Harries, Mark & Ian Smith. (2002). The development and clinical use of trastuzumab (Herceptin).. Endocrine Related Cancer. 9(2). 75–85. 139 indexed citations
19.
Harries, Mark & Martin Gore. (2002). Part I: Chemotherapy for epithelial ovarian cancer–treatment at first diagnosis. The Lancet Oncology. 3(9). 529–536. 129 indexed citations
20.
Harries, Mark & Stanley B. Kaye. (2001). Recent advances in the treatment of epithelial ovarian cancer. Expert Opinion on Investigational Drugs. 10(9). 1715–1724. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marta Gil-Martín Breakdown of academic impact, for papers by Paula R. Pohlmann Breakdown of academic impact, for papers by Franco Di Filippo Breakdown of academic impact, for papers by Thierry Petit Breakdown of academic impact, for papers by Alberto Gallardo Breakdown of academic impact, for papers by Juan J. Roman Breakdown of academic impact, for papers by Natália Buza Breakdown of academic impact, for papers by Richard Lubin Breakdown of academic impact, for papers by Jean‐Pascal Machiels Breakdown of academic impact, for papers by Christian Rudlowski
Rankless by CCL
2026